An Open-label, Randomized, Single-dose, Crossover Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects
Latest Information Update: 13 Jun 2025
At a glance
- Drugs DA 5223 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
Most Recent Events
- 13 Jun 2025 New trial record